Opinion
avacOpinion

Global Health Watch: NIH Orders Pause on HIV Trials, Zimbabwe + Zambia Health MoUs, WHO + Global Fund leadership, Foreign Assistance Funds

The US National Institutes of Health (NIH) said its HIV clinical trial networks should “temporarily hold off on launching new studies that had not yet enrolled participants and that would not be ...
avac

Global Health Watch: Billions in Question, NIH + America First Plans, WHO + Global Fund Leadership & PPPR Rejection

The US fiscal year ended this week amid questions about the billion dollars in Congressionally-appropriated foreign assistance, while new strategies for HIV research at the National Institutes of ...
avac

Artificial Intelligence in the HIV response: All the good stuff from AIDS2026

An analysis by Jirair Ratevosian of the Duke Global Health Institute looked comprehensively at AI-related abstracts, key themes from use cases, and emerging trends at AIDS 2026. His review shows the ...
avac

Global Health Watch: White House Drops NIH Review Plan, NIAID Reorg Moves Fwd, Prep for Generic LEN Access, Accra Reset

There is no shortage of global health news this week. Against the backdrop of the UN General Assembly (UNGA 81), this issue covers efforts to reshape the global health architecture through the Accra ...
avac

The Clinical Trial Design Academy: Equipping Advocates to Shape HIV Prevention Research Decisions and Move the Research Agenda Forward

HIV prevention research must be conducted in collaboration with the communities it intends to serve; decisions about study design, participant populations and locations, conduct, and future access ...
avac

Global Health Watch: NIH-DoD Deal & NIAID Restructuring, Ebola Vaccine Progress, Gavi Funding Resumes, New US Foreign Aid Leadership

The US National Institutes of Health (NIH) signs a 10-year agreement that could move significant NIAID research funding to the Department of Defense, as NIAID separately proposes a major restructuring ...
avac

The Impact Report: Two Decades of Good Participatory Practice in HIV Research

Scientific breakthroughs in HIV prevention depend on community engagement that drives successful research, development, acceptance and uptake of new products. In 2007, emerging from controversies that ...
avac

Harnessing Artificial Intelligence for HIV: Breakthrough or Buzzword?

This presentation by Izukanji Sikazwe, Head of HIV at The Global Fund, during AIDS 2026 explores how the field might harness artificial intelligence in response to HIV. Izukanji Sikazwe unpacks what ...
avac

EXPrESSIVE-11 Communications Toolkit

Downloadable materials to foster community interest, awareness and engagement in the EXPrESSIVE-11 trials, tailored to the local languages and reflecting the lived realities of communities in ...
avac

Alimatravir (AMI) for PrEP

Alimatravir (AMI) is an investigational monthly pill for HIV prevention developed by Merck/MSD. AMI is currently in phase 3 efficacy trials: EXPrESSIVE-10 and EXPrESSIVE-11. EXPrESSIVE-10 launched in ...
avac

Embedding Good Participatory Practice in PURPOSE 1

Gilead’s PURPOSE program is comprised of six clinical trials investigating the efficacy of long-acting injectable lenacapavir (LEN) for PrEP among diverse populations. PURPOSE 1, the first trial in ...
avac

Using a Transformative Human-Centered Design Approach to Co-Create Communication Materials for the Alimatravir Efficacy Trial, EXPrESSIVE-11

Merck’s EXPrESSIVE program is investigating the efficacy of alimatravir (AMI) for monthly oral PrEP. With support from the Gates Foundation, AVAC works to ensure there is strong, consistent engagement ...